Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura

Blood

Volumn 98, Issue 4, 2001, Pages 952-957

  Stasi, Roberto ^a,b   Pagano, Adalberto ^a,b   Stipa, Elisa ^a,b   Amadori, Sergio ^a,b  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; CD20 ANTIGEN; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PARACETAMOL; PREDNISONE; RHESUS D ANTIBODY; RITUXIMAB; SEROTONIN ANTAGONIST; VINCRISTINE;

ADULT; AGED; ARTICLE; ASTHENIA; CARDIOVASCULAR DISEASE; CHILL; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LYMPHOCYTE COUNT; MALE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SINUS TACHYCARDIA; SPLENECTOMY; THROMBOCYTE COUNT; TREATMENT FAILURE; TREATMENT OUTCOME; VERTIGO; VOMITING;

EID: 0035883071     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.4.952     Document Type: Article

References (22)

1. George JN, El-Havake MA, Raskob GE. Chronic idiopathic thrombopenic purpura. N Engl J Med. 1995;331:207-211.
2. George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3-40.
3. Diagnosis and treatment of idiopathic thrombocytopenic purpura: recommendations of the American Society of Hematology. The American Society of Hematology ITP Practice Guideline Panel. Ann Intern Med. 1997;126:319-326.
4. McMillan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med. 1997;126:307-314.
5. Stasi R, Stipa E, Masi M, et al. Long-term observation of adults with chronic idiopathic thrombocytopenic purpura: a study of 208 cases. Am J Med. 1995;98:436-442.
6. McMillan R. Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. Semin Hematol. 2000;37:239-248.
7. Semple JW, Lazarus AH, Freedman J. The cellular immunology associated with autoimmune thrombocytopenic purpura: an update. Transfus Sci. 1998;19:245-251.
8. Aster RH, George JN, McMillan R, et al. Workshop on autoimmune (idiopathic) thrombocytopenic purpura: pathogenesis and new approaches to therapy. Am J Hematol. 1998;58:231-234.
9. Einfeld DA, Brown JP, Valentine MA, et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988;7:711-717.
10. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
11. Stasi R, Stipa E, Masi M, et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood. 1994;84:4203-4208.
12. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-3274.
13. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-2195.
14. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
15. Perotta A, Sunneberg TA, Scott J, et al. Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura [abstract]. Blood. 1999;94:49a.
16. Saleh MN, Gutheil J, Moore M, et al. A pilot study of anti-CD20 MoAb rituximab in patients with refractory immune thrombocytopenic purpura (ITP) [abstract]. Blood. 2000;96:252a.
17. Bussel JB. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol. 2000;37:261-266.
18. Czuczman MS, Grillo-López AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
19. Berchtold P, Muller D, Beardsley D, et al. International study to compare antigen-specific methods used for the measurement of antiplatelet autoantibodies. Br J Haematol. 1997;96:477-483.
20. Karpatkin S. Autoimmune idiopathic thrombocytopenic purpura. Lancet. 1997;349:1531-1536.
21. Figueroa M, Gehlsen J, Hammond D, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med. 1993;328:1226-1229.
22. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85:351-358.